Lexicon Pharmaceuticals

At the Leerink conference, Lexicon Pharmaceuticals set its strategic focus on cardiometabolic diseases and chronic pain, prioritizing late‑stage programs. The company plans a resubmission of the NDA for Zynquista in type 1 diabetes, the SONATA Phase‑3 study of sotagliflozin in HCM will complete recruitment by midyear, and a Phase‑3 design for pilavapadin in DPNP has been agreed with positive FDA feedback. The partnership with Novo Nordisk for LX9851 has hit milestones (USD 10 million) with further payments possible, while regulatory approval risks and competitive pressure remain key challenges. » More on de.investing.com

Lexicon Pharmaceuticals reported Q4 2025 EPS of -$0.04 (expected -$0.07) and revenue of $5.5 million versus projected $3.92 million. The company sharply cut R&D and SG&A expenses and significantly improved its net loss year over year. Despite the stronger metrics, the stock fell about 4.3% in premarket trading. For 2026, Lexicon expects total operating costs of $100–$110 million and is focusing investments on its cardiometabolic platform, including sotagliflozin and a resubmission for Zynquista. » More on de.investing.com

Lexicon Pharmaceuticals completed a public offering and a concurrent private placement, raising about $100 million. In the public offering, 32 million common shares were sold at $1.30 per share; in addition, investors placed 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 each. The proceeds are intended to fund research and development, working capital and general corporate purposes and strengthen the balance sheet, although the company continues to show negative EBITDA and gross margins; the liquidity metric remains high with a current ratio of 5.64. » More on de.investing.com